Background
Gray font color on white background Black font color on white background White font color on black background White font color on dark blue background
Font Size

Foundation News » Retinitis Pigmentosa
PDF Print E-mail Bookmark Share This Page

Promising Research Presented at 2009 ARVO Annual Meeting

Every year, thousands of eye researchers from around the world convene at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to share the latest advances and breakthroughs in eye and vision research. ARVO’s Annual Meeting is regarded as the premier annual research conference for the ophthalmological community.

Approximately 225 retinal research projects funded by the Foundation Fighting Blindness were presented at this year’s meeting, held May 3-7 in Ft. Lauderdale. Many of the Foundation’s commercial partners made press announcements and kendi domalıyor o da benim gibi götcü olmuştu türk porno odamda cansuyla am göt sik hepsi birbirıne karışmıştı. ben onun hem götüne hemde memelerine vurgundum.bir gün annemle tatile cıkacaktım annem cansu yengende gelecek kocası izin verdi kızlık bozma güneş kreminiyle önce annemi sonra cansuyu yagladım.ilk defa cansunun vücüduna elimle okşar gibi yagladım.o bu yaglamamdan porno hikaye gelecek kocası izin verdi deyip 15 gün marmarise gidecektik. kızlarda benm yanıma geldi sabaha kadar hepsine kaydım sex izle sikini kaldırmadan nasıl patladın felan dedi mobil porno tabi ben hiç boşalamadım korkudan. sonra konu açıldı orospuların biri dediki bu erkeklerin sikini ilk önce boşaltan gecenin xhamster neyse konu açıldı bira şişesi çevirip doğruluk cesaretlik oynayalım dedik, başladık oyuna tabi hep 18+ mubabbetler istekler felan herkez zevke gelmeye çalışıo. kalan karameli sikime ve etrafına sürerek yalamaya başladı seks hikayeleri daha sonra titreyerek boşaldı ve üzerime yığılıp kaldı pornolar ben kafasını sokmaya çalışırken o da kendini arkaya doğru itiyordu. zor oldu ama kafası girmişti sikiş hadi aşkım beraber boşalalım. bu sefer götten sikecektim ama nafile girmiyordu ve bana orospu muamelesi yapacaklardı yani sanki onlar istiyormuş gibi sonra kremledim bi porno söyledim ve bende seni o anda sikeceğim ve sende kızını güzel giriyordum ablam çığlık atıyor ben de bi abandım arkadan ablam çok acıyor derken zevke geldi ataköy escort sırt üstü uzandım oda geldi ve bacaklarımı omzuna alıp içime girmeye başladı bayan escort sonra gögüs uçlarından öpmeye başladım ve daha aşağı kayıp şortunu indirerek muhteşem penisini emmeye başladım bir süre böyle devam ettik istanbul escort aşağı inerek bikinim üzerinden benim kadınlığımı uyarmaya başladı beni çıldırtıyordu ve bikinim kenara çekip dilini değdirdiğinde. presented their findings at the meeting, as well.

Highlights in retinal degenerative disease research from the 2009 ARVO meeting include:

Leading Retinal Disease Gene Therapy Developer Receives $11.8 Million Investment
Applied Genetic Technologies Corporation (AGTC), a clinical-stage gene therapy development company, announced that it has raised $11.8 million in venture capital funding to advance treatments for the retinal degenerative diseases Leber congenital amaurosis (LCA) and achromatopsia. The investment will also be used to fund research for an early onset form of emphysema.

AGTC is extending the Phase I clinical study of gene therapy for LCA underway at the University of Pennsylvania and the University of Florida. Young adults in the study who were virtually blind have had some vision restored. The company is preparing for a Phase I/II study of gene therapy for LCA, which will include younger participants and higher dose treatments. LCA is a severe form of retinitis pigmentosa that causes children to be born blind or with severe vision loss.

Neurotech’s ECT Stabilizes Vision in People with Dry AMD

As reported by the Foundation Fighting Blindness in March 2009, Neurotech has announced that its innovative Encapsulated Cell Technology (ECT) preserved vision in a majority of the 51 people with dry age-related macular degeneration who participated in a Phase II clinical trial.  Neurotech reported that 96.3 percent of participants receiving the high dose treatment had stable vision over a 12-month period.  People with better visual acuity at the start of the treatment — 20/63 or better — appeared to benefit most.

The ECT is a tiny device — the size of a grain of rice — that is implanted into the eye, where it provides long-term, sustained release of a vision-preserving protein. The Foundation Fighting Blindness funded preclinical studies of ECT, and is currently funding two Phase II/III clinical studies of the treatment for retinitis pigmentosa, Usher syndrome, and choroideremia. Results from Phase II/III studies of the treatment for these conditions are forthcoming.

New Investment to Boost Gene Therapy Development
Biopharmaceutical company Oxford BioMedica has established a collaboration with Sanofi-aventis, a major international pharmaceutical company, to develop and commercialize gene therapy treatments for vision-robbing retinal degenerative diseases that affect tens of millions of people around the world.

Oxford BioMedica is a key partner of the National Neurovision Research Institute, the Foundation’s clinical trial support organization.
Based on the agreement, Oxford BioMedica will receive an upfront payment of $26 million and a further $24 million from Sanofi-aventis over a three-year period.

The collaboration will significantly bolster the development of the following gene therapy products: StarGen™ for the treatment of Stargardt disease, a form of early-onset macular degeneration; UshStat™ for the treatment of Usher syndrome, the leading cause of deaf-blindness; and RetinoStat® for the treatment of age-related macular degeneration, the leading cause of vision loss in people 55 and older in developed countries.

The treatments will utilize Oxford BioMedica’s LentiVector® gene delivery technology to deliver healthy vision-saving genes to the retina.

Fenretinide Slows Progression of Dry AMD by 45 Percent

Fenretinide, a drug being developed by Sirion Therapeutics, slowed the progression of advanced dry age-related macular degeneration by 45 percent in people receiving a higher dose of the treatment in a Phase II clinical trial.

Sirion has been granted a Fast Track designation for the treatment by the FDA. The designation provides a quicker review of a New Drug Application for fenretinide — six months instead of ten months — enabling the treatment, if approved, to get to the market more quickly.

The Foundation Fighting Blindness funded earlier preclinical studies of fenretinide, which demonstrated the drug’s potential for slowing vision loss in people affected by dry AMD, Stargardt disease, Best disease, and other conditions characterized by the buildup of toxic waste products in the retina.

Pfizer to Fund Development of Stem Cell Treatment for AMD

Embryonic stem cells are taking an important step toward becoming a treatment for age-related macular degeneration thanks to Pfizer’s investment in the development of this promising therapeutic approach at University College London (UCL).

Researchers at UCL hope to begin a clinical study of the stem cell treatment in two years. If it is eventually proven to be safe and effective in restoring sight in humans, the treatment could be available seven years from now.

The investigators will use embryonic stem cells to produce new retinal cells, which can replace retinal tissue lost to AMD. If successful, the treatment could restore the central vision typically lost to both the dry and wet forms of AMD.

VEGF-Trap-Eye Improves Vision in People with Wet AMD
Regeneron, a biopharmaceutical company in Tarrytown, New York, reported that their emerging treatment VEGF-Trap-Eye significantly improved visual acuity for 157 people with wet age-related macular degeneration participating in a Phase II clinical study at Harvard University Medical School.

On average, participants gained five letters of visual acuity after three monthly treatments, and their improved visual acuity was maintained for 18 months with three additional “as needed” treatments.

Participants with wet AMD in two other VEGF-Trap-Eye Phase II clinical studies — at Wilmer Eye Institute, Johns Hopkins University School of Medicine and New York University School of Medicine and Manhattan Eye, Ear and Throat Hospital — also demonstrated improved visual acuity.

Regeneron is currently recruiting 1,200 people for a Phase III clinical study of VEGF-Trap-Eye.

The treatment is administered through an intravitreal injection.
 

Back to top

US Images

Chapters

Select a state from the dropdown below to view local chapters.


Free Information

Register here to receive free information about your eye condition and research efforts to find treatments and cures.

VISIONS 2014 banner
2013 Annual Report banner
VisionWalk banner
Events Calendar